Références :

  1. Keene BW, Atkins CE, Bonagura J, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Int Med 2019:1-14.

  2. Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med 2012;26:1337-1349.

  3. Boswood A, Haggstrom J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study – a randomized clinical trial. J Vet Intern Med 2016;30:1765.

    Vetmedin® est une marque déposée de Boehringer Ingelheim Vetmedica GmbH, utilisée sous licence.
    © 2022 Boehringer Ingelheim Santé Animale Canada Inc.

1200px-Boehringer_Ingelheim_Logo.svg